身体活动干预措施来改善第一发精神病的认知:我们到目前为止所知道的
Cinzia Perlini1, Maria Gloria Rossetti2,3, Francesca Girelli4
1Section of Clinical Psychology, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
概括
身体活动可以改善记忆力,注意力和首发精神病 (FEP) 的执行功能. 然而,需要更严格的研究来确认这些认知益处,并了解它们的长期影响.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 康复 康复 康复 康复
背景情况:
- 认知障碍是精神病的关键特征,影响功能和生活质量.
- 第一发精神病 (FEP) 患者在处理速度,记忆,注意力和执行功能方面表现出缺陷,对药物反应不佳.
- 身体活动对精神分裂症谱系障碍的认知改善有希望,但对FEP的数据有限.
研究的目的:
- 审查体育活动干预措施在患有第一发精神病 (FEP) 个体中增强认知功能的潜力.
主要方法:
- 在2024年3月,在PubMed,PsycINFO和Web of Science进行了系统的文献搜索.
- 审查了六项符合纳入标准的研究,所有这些研究都检查了结构化体育活动对FEP认知功能的影响.
主要成果:
- 初步结果表明,体育活动干预可以提高FEP患者的记忆力,注意力和执行功能.
- 这些干预措施对社会认知或运动功能没有显著影响.
结论:
- 由于研究设计和干预方案的差异,目前的证据不足以得出确定的结论.
- 需要进一步进行高质量的研究,以验证认知效益,评估耐用性,并探索潜在机制.
相关概念视频
Cognitive Development During Adulthood
50
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
50
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
95
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
95
Psychosis: Goals of Pharmacotherapy
103
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
103
Alzheimer's Disease: Treatment
162
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
162
Negative and Cognitive Symptoms of Schizophrenia
43
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
43
Parkinson's Disease: Treatment
216
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
216


